NEW YORK, Feb. 3, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple conferences in February.
BIO CEO 2014
- Date and Time: Monday, February 10, 2014, 1:00 PM EST
- Venue: The Waldorf Astoria, New York, New York
- Session: Company Presentation
- Speaker: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem
New York Stem Cell Summit 2014
- Date: Tuesday, February 18, 2014
- Venue: The Convene, Downtown, New York, New York
- Session #1 Time: 11:00 AM EST
- Session #1 Topic: Treating the Aging Patient With Stem Cells
- Session #1 Speaker: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem
- Session #2 Time: 3:36 PM EST
- Session #2 Topic: Cutting Time to Market for Stem Cell Suppliers
- Session #2 Speaker: Robert A. Preti, PhD, Chief Scientific Officer of NeoStem and PCT and President of PCT
GTC Cell & Gene Therapy Conference
- Venue: Hyatt Regency Mission Bay, San Diego, California
- Session #1 Date and Time: Thursday, February 20, 2014, 1:30 PM PST
- Panel Topic: Emerging Technologies
- Panel Moderator: Robert A. Preti, PhD, Chief Scientific Officer of NeoStem and PCT and President of PCT
- Session #1 Topic: The Emerging Technology is Intrinsic Biotechnology
- Session #1 Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development and New Technologies of NeoStem
- Session #2 Date and Time: Friday, February 21, 2014, 1:40 PM PST
- Panel Topic: Strategies for Commercialization
- Panel Moderator: Robert A. Preti, PhD, Chief Scientific Officer of NeoStem and PCT and President of PCT
- Session #2 Topic: Considerations for a Commercially Successful Cell Therapy Product
- Session #2 Speaker: Sanjin Zvonic, PhD, Director, Technology & Business Development, PCT
About NeoStem, Inc.
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
For more information, please visit www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the successful development of cellular therapies, including with respect to AMR-001 and regulatory T cells, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.